Low Float (MYNZ) Is A Nasdaq Past Champ And Breakout Idea With 5 Huge Potential Catalysts

We've got a ton to go over, so dig in. This is going to take a minute. Low Float (MYNZ) Is A Nasdaq Past Champ And Breakout Idea With 5 Huge Potential Catalysts March 2nd Dear Reader, We've got a ton to go over, so dig in. This is going to take a minute. When I delivered this past champ to your inboxes originally, it went absolutely bonkers. Running an insane 200+% (approx.) in the short term, it turned into a stunning multi-dollar mover. With its breakout potential starting to grow again, I brought it back to attention only to watch it pop another 30+% in a very little period of time. And most recently when I brought it to your attention on December 5th after it closed at $7.80, it made a $1.00+ (14%) approximate move to a high of $8.95 the next day. So when I saw it had [2 press]( [releases]( out this week, a low float of fewer than 11Mn shares, an average analyst price target of $18.00, and key IP acquisition news in 2023, I realized it needed to be back on alert immediately. For Thursday, March 2nd, there is only one Nasdaq profile to have on your watch-list: *Mainz Biomed B.V. (MYNZ)* Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert, an accurate, non-invasive, and easy-to-use early detection diagnostic test for colorectal cancer. And right now, 5 potential catalysts could provide this profile with a breakout spark near term. Here's what to know: No. 1 - Low Float Volatility Could Be On Display Daily No. 2 - Two Different Analysts Provide An Average Price Target Of $18 No. 3 - Acquisition Of IP Portfolio Could Act As An Important Value Generation Milestone No. 4 - MYNZ Adds To European Network Of Lab Partners (Enters Markets In Spain & UK) No. 5 - 2022 Company Highlights Provide Key Insights Of A Potentially Transformative Year Ahead But more on those in a second... About MYNZ: Early Identification Of Cancer Saves Lives Mainz BioMed – founded in Mainz, Germany and aiming to become a leading provider of easy-to-use diagnostic solutions for patients everywhere. Developing market-ready molecular in-vitro diagnostics tests since 2010. Their goal is to place effective solutions where they need to be… In your hands. A Blockbuster Early Detection Test for Colorectal Cancer Significant Impact: Colorectal cancer is the 2nd most lethal cancer in the US, but also highly preventable; with early detection providing 5-year survival rates above 90%. Revenue Generating: ColoAlert is CE-IVD marked and is approved for sale in Europe. European sales will provide near-term revenue potential, while we prepare our entry into the US market. Process launched in 1Q2022. U.S. Markets: We have begun the FDA process. Recent FDA guidance recommends colorectal cancer screening for everyone over the age of 45, which translates to market potential of over 52Mn tests per year. Ease of Use: Non-invasive test, which can be taken at home, with rapid response of 92% specificity and 85% sensitivity (which is expected to be increased for the FDA product). Designed to be easier to administer than Exact Science’s ColoGuard, more accurate than FIT, and much less invasive than a colonoscopy. Experienced Management: Seasoned and experienced management, board & advisors with particular skill sets in commercializing and monetizing medical diagnostics at some of the largest medical companies in the world. Attractive Valuation: They believe their current valuation holds tremendous upside. ColoAlert - Simple, Fast, Accurate and Non-Invasive - A PCR-based CRC early detection stool test - Non-invasive, no preparation or sedation, no time off work - 98% patient satisfaction – Easy product to use - Designed to offer affordable CRC screening solutions [Grab more key details and sources here.]( ----- Mentioned above, MYNZ has 5 potential catalysts that could provide it with a near term breakout spark. Check them out: No. 1 MYNZ Potential Catalyst - Low Float Volatility Could Be On Display Daily According to the [Yahoo Finance website]( MYNZ has a low float. The website reports this profile to have approximately 10.56Mn shares in its float. Why is that important? It's important on one crucial level. Volatility. Could more 2023 positive company news help provide a near term spark? ----- No. 2 MYNZ Potential Catalyst - Two Different Analysts Provide An Average Price Target Of $18 Wow. Over at [TipRanks]( I found this: From Wednesday's closing valuation, MYNZ is displaying a ton of potential upside to this $18 average target. In fact, that's over 125+% potential upside. Now, I'm not saying this profile is going to surge to $18 this week, but the potential needs to be noted. And with a 52-week high of $17.81, that price target might not be all that far-fetched. ----- No. 3 MYNZ Potential Catalyst - Acquisition Of IP Portfolio Could Act As An Important Value Generation Milestone Mainz Biomed Acquires Entire Intellectual Property Portfolio for its Colorectal Cancer Diagnostic Test Program BERKELEY, Calif. and MAINZ, Germany, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the execution of its option from Uni Targeting Research AS to acquire all of the previously licensed scientific intellectual property (“IP”) for its flagship product ColoAlert, a highly efficacious, and easy-to-use detection test for colorectal cancer (“CRC”) being commercialized across Europe. ... “This is an important value generation milestone for us as we continue executing our commercial strategy and product development plan to ultimately bring to market the gold-standard CRC self-administered diagnostic test,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “Securing complete IP ownership is integral to our growth strategy as it streamlines administration, reduces per-test expenses, and provides us the opportunity to ramp-up corporate development activities,” added Baechler. ... [Read the full article here.]( ----- No. 4 MYNZ Potential Catalyst - MYNZ Adds To European Network Of Lab Partners (Enters Markets In Spain & UK) Mainz Biomed Expands European Commercial Footprint and Enters Markets in Spain and UK Continued roll-out in Europe with onboarding of new lab partners BERKELEY, Calif. and MAINZ, Germany, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the establishment of commercial partnerships for ColoAlert with Marylebone Laboratory (Marylebone Lab LTD) and Instituto de Microecologia, two leading independent laboratories covering England and Spain. ColoAlert, Mainz Biomed’s flagship product, a highly efficacious and easy-to-use, at-home detection test for colorectal cancer (CRC), is currently being commercialized across Europe and in select international markets via a differentiated business model of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility. ... [Read the full article here.]( ----- No. 5 MYNZ Potential Catalyst - 2022 Company Highlights Provide Key Insights Of A Potentially Transformative Year Ahead Mainz Biomed Provides Year-End 2022 Corporate Review BERKELEY, US and MAINZ, Germany , Jan. 03, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a corporate summary for the fiscal year ended December 31, 2022. Key Commercial, Operational and Product Development Highlights - Launched U.S.-based eAArly DETECT study by enrolling the first patient; study focused on the performance of Mainz Biomed’s mRNA biomarkers in identifying Advance Adenomas (AA), a type of pre-cancerous polyp often attributed to colorectal cancer (CRC); on track to report results in 1H 2023. - Initiated ReconAAsense, U.S. Pivotal Clinical Study with Company’s CRC screening test; anticipate commencing patient enrollment in mid-2023. - Continued executing differentiated business model of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility. - Ramped up international commercial activities for ColoAlert, the Company’s highly efficacious and easy-to-use detection test for CRC, including five new lab partners in Germany and Italy. - Enhanced leadership team with appointments to Board of Directors and Company executives to lead commercial and product development groups, with former executives and senior management from Roche, Abbott, Luminex, and Qiagen; expanded Medical Advisory Board of global leaders in molecular diagnostic development. - Initiated and commenced patient enrollment in ColoFuture, a European study evaluating the integration of a portfolio of novel gene expression (mRNA) biomarkers into ColoAlert; potential to identify advanced adenomas, a type of pre-cancerous polyp often attributed to CRC; with results expected in 2023. - Achieved multiple preclinical milestones supporting the continued development of PancAlert, a potential first-in-class screening test for pancreatic cancer. - Acquired a portfolio of novel mRNA biomarkers to upgrade ColoAlert’s technical profile to achieve “gold standard” status for AA and CRC at-home testing. - Executed a USD 25.8Mn (gross) public follow-on offering. “The past year has proven to be an extraordinary period of growth as we strengthened every aspect of the Company while expanding our international commercial footprint and executing our product development programs,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “We head into 2023 with a great deal of momentum, and on behalf of the management team and Board of Directors, I wish to extend gratitude to our shareholders for their support as we continue our journey to become a leading provider of cancer-focused early detection and disease prevention molecular diagnostics.” ... [Read the full article here.]( ----- MYNZ Recap - 5 Must-Know Potential Catalyst For This Nasdaq Past Champ No. 1 - Low Float Volatility Could Be On Display Daily No. 2 - Two Different Analysts Provide An Average Price Target Of $18 No. 3 - Acquisition Of IP Portfolio Could Act As An Important Value Generation Milestone No. 4 - MYNZ Adds To European Network Of Lab Partners (Enters Markets In Spain & UK) No. 5 - 2022 Company Highlights Provide Key Insights Of A Potentially Transformative Year Ahead ----- Coverage is officially reinitiated on MYNZ. When time permits, do this: Get MYNZ on your radar now. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Ownership of FI has now moved to a single individual. Disclosure: I am not a lic-ensed fina-ncial adviser. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. Fierce full disclosure is to be read and fully understood before using Fierce's website, or joining Fierce's email or text list. By viewing Fierce's website and/or reading Fierce's email or text newsletter you are agreeing to -> [( An owner of SWN Media LLC owns and operates smallcapfirm . com (“SCF”), owns and operates stockwirenews . com (“SWN”), and owns and operates stockstreetwire . com ("SSW"). From time to time, SWN, SCF, FI, and/or SSW will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between StockNewsWire LLC and Awareness Consulting Network LLC, StockWireNews was hired for a period beginning on 12/8/21 and ending on 12/9/21 to publicly disseminate information about (MYNZ) via Website, Email and SMS. We were paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (MYNZ). Pursuant to an agreement between SWN Media LLC and TD Media LLC, StockWireNews has been hired for a period beginning on 6/6/22 and ending on 6/7/22 to publicly disseminate information about (MYNZ) via Website, Email and SMS. SWN Media LLC was paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (MYNZ). Pursuant to an agreement between SWN Media LLC and Awareness Consulting Network LLC, StockWireNews has been hired for a period beginning on 9/27/22 and ending on 9/29/22 to publicly disseminate information about (MYNZ) via Website, Email and SMS. SWN Media LLC was paid twenty-two thousand five hundred USD via bank wire transfer. We own zero shares of (MYNZ). Pursuant to an agreement between SWN Media LLC and Awareness Consulting Network LLC, FierceInvestor (FI) has been hired for a period beginning on 12/5/22 and ending on 12/7/22 to publicly disseminate information about (MYNZ) via Website, Email and SMS. SWN Media LLC was paid twenty-two thousand five hundred USD via bank wire transfer. We own zero shares of (MYNZ). Pursuant to an agreement between SWN Media LLC and Awareness Consulting Network LLC, FierceInvestor (FI) has been hired for a period beginning on 3/1/23 and ending on 3/2/23 to publicly disseminate information about (MYNZ) via Website, Email and SMS. SWN Media LLC was paid twenty-two thousand five hundred USD via bank wire transfer. We own zero shares of (MYNZ). To date we have now been compensated a total of one hundred twenty-two thousand five hundred USD via bank wire transfer to disseminate information about (MYNZ). A member of SWN Media LLC is also a member of TD Media LLC. Pursuant to an agreement between TD Media LLC and Awareness Consulting Network LLC, TD Media LLC has been hired for a period beginning on 07/07/2022 and ending on 07/15/2022 to publicly disseminate information about (MYNZ:US) via digital communications. We have been paid an additional twenty two thousand five hundred dollars USD via bank wire transfer. To date we have been paid five hundred forty one thousand nine hundred fifty dollars USD via bank wire transfer to disseminate information about (MYNZ:US) via digital communications. We own zero shares of (MYNZ:US). [( Fierce | 539 W Commerce St, Dallas, TX 75208 [Unsubscribe {EMAIL}]( [Update Profile]( | [Constant Contact Data Notice]( Sent by jaks@fierceanalyst.net